4D Biomaterials

InvenireX is a biotech company that provides molecular diagnostics services.

Artios is an independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programs, including through a unique partnership with Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK.

PACT creates stylish products made in harmony with the environment by developing innovative, eco-friendly biomaterials sourced from natural ingredients like collagen, herbal extracts, oils, and minerals.

Mission Therapeutics is a drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

At OXCCU, we are leading the way in scientific progress, shaping the future of sustainable energy, fuel production, and the creation of chemicals and plastics. Our approach involves combining CO2 from the air with H2 from water and renewable electricity to produce environmentally friendly fuels, chemicals, and biodegradable plastics. Carbon is a highly valuable element, particularly when utilized in hydrocarbons. Our objective is to allow future generations to continue using hydrocarbon fuels without negatively impacting the climate. While renewable energy is becoming more prevalent, fossil fuels still account for a significant portion (82%) of the world's primary energy demand of 604 EJ in 2022. In order to minimize greenhouse gas emissions, we must transition to zero-emission sources within a 30-year timeframe. While some sectors, such as power, are already progressing in this direction, not all industries can easily decarbonize using renewable electricity alone. Specifically, long-distance aviation fuels and petrochemicals present challenges due to their need for high energy density and the carbon molecules required to produce a variety of everyday products. Here is where OXCCU provides a unique solution. Our cost-effective catalysts demonstrate exceptional efficiency and selectivity, converting CO2 into valuable hydrocarbons through an innovative one-step process. CO2 can be transformed into sustainable e-fuels, chemicals, and biodegradable plastics. This represents the future of truly circular technological advancement, where individuals can travel by air, use household chemicals, and purchase disposable and biodegradable plastic products without concerns about their contribution to climate change or waste disposal. The company was established in 2021 as a spinoff from the University of Oxford by co-founders Andrew Symes and Jane Jin, who were employed at IP Group and OUI respectively. The scientific foundations of the company are supported by breakthrough research published by the academic founders, Professor Peter Edwards, Dr Tiancun Xiao, and Dr Benzhen Yao, in highly reputable scientific journals.

Forge Genetics is a startup with proprietary Forge Editing technology, bypassing CRISPR patents for precision gene-editing services.

BoobyBiome uses specialist expertise and research to develop a probiotic supplement for infants with compromised microbiomes. We aim to promote healthy infant development by recreating the beneficial bacteria associated with breast milk.

Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development. Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies. Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease.

NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function and slow or halt the progression of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease and motor neurone disease. Founded in 2018 by a team of experienced biotech and pharmaceutical industry professionals, with a background in neuroscience drug discovery, NRG Therapeutics will initially focus on the discovery and development of brain penetrant mitochondrial permeability transition pore inhibitors for the treatment of Parkinson’s disease.

Neurovalens provides cutting-edge solutions in the realms of neuroscience, bioscience, and neurophysiology. With backing from Invest NI through the EU's Investment for Growth and Jobs Programme, Neurovalens' project will focus on research and development over the coming year to enhance the company's competitiveness.

LIfT Biosciences® has a breakthrough allogeneic innate immuno-cell therapy platform called Neutrophil Only Leukocyte Infusion Therapy (N-LIfT®) that allows us to produce different types of Immunomodulatory Alpha Neutrophils (IMAN®s) at scale from iPSCs for a wide range of different purposes as a mono or combo. LIfT BioSciences was founded in 2016 and headquartered in London, England.

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility. The Company is a clinical-stage biopharmaceutical group developing new medicines and treatments for life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.